Greg Moeck

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Venues

Antimicrobial agents and chemotherapy

The Journal of antimicrobial chemotherapy

The Medicines Company (Canada)

McGill University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The Medicines Company (Canada)

Canada

VP, Biology :: Biology, Infectious Diseases Care

Education History

McGill University

Canada

PHD :: Microbiology and Immunology

Publications

James A Karlowsky, Mark G Wise, Meredith A Hackel, David A Six, Tsuyoshi Uehara, Denis M Daigle, Daniel C Pevear, Greg Moeck, Daniel F Sahm
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. The Journal of antimicrobial chemotherapy (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Michael R Jacobs, Ayman M Abdelhamed, Caryn E Good, Andrew R Mack, Christopher R Bethel, Steven Marshall, Andrea M Hujer, Kristine M Hujer, Robin Patel, David Van Duin, Vance G Fowler, Daniel D Rhoads, David A Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M Papp-Wallace, Robert A Bonomo
ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime. Antimicrobial agents and chemotherapy (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
G Ralph Corey, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N Dudley, William O'Riordan, null null
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Antimicrobial agents and chemotherapy 62 (4) (2018)
Adam Belley, Francis F Arhin, Greg Moeck
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial agents and chemotherapy 62 (1) (2017)

Greg Moeck.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Greg Moeck